



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



CVT-6883

Item No. 33333

CAS Registry No.: 752222-83-6
Formal Name: 3-ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione
Synonym: GS-6201
MF: C₂₁H₂₁F₃N₆O₂
FW: 446.4
Purity: ≥98%
UV/Vis.: λ_{max}: 236, 304 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CVT-6883 is supplied as a solid. A stock solution may be made by dissolving the CVT-6883 in the solvent of choice, which should be purged with an inert gas. CVT-6883 is soluble in DMSO.

Description

CVT-6883 is an adenosine A_{2B} receptor antagonist (K_i = 22 nM).¹ It is selective for adenosine A_{2B} over adenosine A₁, A_{2A}, and A₃ receptors (K_is = 1,940, 3,280, and 1,070 nM, respectively), as well as a panel of 84 receptors, ion channels, transporters, and enzymes at 10 μM. CVT-6883 (6 mg/kg) decreases allergen challenge-induced bronchoalveolar lavage fluid (BALF) eosinophil and lymphocyte infiltration and airway reactivity in a mouse model of allergic asthma.² It also decreases fibrosis in the non-infarct zone, improves ejection fractions, and reduces ventricular tachycardia in a rat model of myocardial infarction.³

References

1. Elzein, E., Kalla, R.V., Li, X., *et al.* Discovery of a novel A_{2B} adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. *J. Med. Chem.* **51(7)**, 2267-2278 (2008).
2. Mustafa, S.J., Nadeem, A., Fan, M., *et al.* Effect of a specific and selective A_{2B} adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. *J. Pharmacol. Exp. Ther.* **320(3)**, 1246-1251 (2007).
3. Zhang, H., Zhong, H., Everett, T.H., 4th, *et al.* Blockade of A_{2B} adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. *Heart Rhythm* **11(1)**, 101-109 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/08/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM